Paul C. Lorigan

机构：Manchester Academic Health Science Centre, University of Manchester, Manchester University NHS Foundation Trust, Cancer Research UK Manchester Institute, The Christie Hospital, The Christie NHS Foundation Trust, Manchester University · ORCID：0000-0002-8875-2164

发表论文 710 篇 · 总被引 65177 次 · h-index 90

代表论文

• Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 study (2025 · The Lancet Oncology · 被引 12)
• Tumour-infiltrating lymphocyte therapy in melanoma: ready for prime time? (2026 · British Journal of Cancer · 被引 9)
• Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: An international retrospective study (2025 · European Journal of Cancer · 被引 9)
• Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma (2025 · Annals of Oncology · 被引 9)
• Cancer diagnoses, referrals, and survival in people with a learning disability in the UK: a population-based, matched cohort study (2025 · The Lancet Regional Health - Europe · 被引 6)
• MANIFEST: Multiomic Platform for Cancer Immunotherapy (2025 · Cancer Discovery · 被引 6)